|1.||Juengwatanatrakul, Thaweesak: 1 article (11/2012)|
|2.||Putalun, Waraporn: 1 article (11/2012)|
|3.||Udomsuk, Latiporn: 1 article (11/2012)|
|4.||Jarukamjorn, Kanokwan: 1 article (11/2012)|
|5.||Kumamoto, Takuya: 1 article (01/2009)|
|6.||Suganami, Akiko: 1 article (01/2009)|
|7.||Ishikawa, Tsutomu: 1 article (01/2009)|
|8.||Tamura, Yutaka: 1 article (01/2009)|
|9.||Takiguchi, Masaki: 1 article (01/2009)|
|10.||Nakanishi, Waka: 1 article (01/2009)|
|1.||Breast Neoplasms (Breast Cancer)
01/30/2009 - "Furthermore, consideration of Lennard-Jones and Coulomb interaction energies of miroestrol and deoxymiroestrol on ERalpha-LBD provided the information to develop the phytoestrogen derivatives as the preferred drug for ER positive breast cancer treatment."
04/01/2005 - "In this report, we have compared the oestrogen agonist and antagonist activity of eight phytoestrogens (genistein, daidzein, equol, miroestrol, deoxymiroestrol, 8-prenylnaringenin, coumestrol and resveratrol) in a range of assays all based within the same receptor and cellular context of the MCF7 human breast cancer cell line. "
11/15/2012 - "The results suggest for the first time that the use of miroestrol and deoxymiroestrol-containing products as alternative medicines or health supplements should be concerned according to their effects on key genes that regulate the bile salt export pump, which could result in the risk of hepatotoxicity and intrahepatic cholestasis."
|2.||Estrogen Receptor alpha